Kineta Inc

OTC Pink - Current Information:KANTUnited States

Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a monoclonal antibody (mAb), immunotherapy targeting VISTA (V-domain Ig suppressor of T cell activation), and an anti-CD27 agonist mAb immunotherapy. KVA12123 may be an effective immunotherapy for many types of cancer, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer (OC), renal cell carcinoma (RCC) and head and neck squamous cell carcinoma. It is also developing an anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The nominated lead candidate is a fully human mAb that demonstrates nanomolar (nM) binding affinity to CD27 in humans.

Contact Information

Headquarters

7683 Se 27Th Street, Suite 481MERCER ISLAND, WA, United States 98040

Phone

206-378-0400

Fax

302-636-5454

Executives

Chairman of the Board

Shawn Iadonato

President, Company Secretary

Craig Philips

Chief Financial Officer

Keith Baker

Chief Scientific Officer

Thierry Guillaudeux

Independent Director

David Arkowitz